Seer, Inc., has announced a significant leap forward with the launch of its advanced Proteograph® Product Suite at the American Society for Mass Spectrometry (ASMS) annual conference in Baltimore. This innovative suite features the Proteograph ONE Assay and the SP200 Automation Instrument, representing Seer's most sophisticated and comprehensive solution to date for scalable, high-resolution, mass spectrometry-based proteomics. This new offering is designed to directly overcome longstanding challenges in large-scale proteomic studies, particularly the limitations of low throughput and prohibitive costs that have historically hindered extensive research.

The new Proteograph workflow dramatically enhances the flagship Proteograph Product Suite's ability to achieve the necessary throughput, efficiency, and depth required for the world's first truly population-scale, deep, and unbiased proteomic studies. By streamlining the workflow, Seer has achieved a transformative milestone, significantly improving the scalability, reproducibility, and affordability of deep proteomic analysis. The system is capable of processing over 1,000 samples per week on a single SP200 instrument, delivering mass spectrometry-based proteomic analysis at a speed, scale, and depth previously considered unattainable. Furthermore, these operational efficiencies and Seer's volume-based pricing model have led to an impressive 60% reduction in the per-sample cost of proteomic analysis compared to the company's initial 2021 release of the Proteograph Product Suite. This substantial cost reduction brings population-scale mass spectrometry proteomics within practical reach, opening new avenues for large-scale biomarker discovery, comprehensive longitudinal disease studies, and extensive multi-center research collaborations.

Seer's Chair and CEO, Omid Farokhzad, emphasized that the introduction of this new Proteograph workflow marks a defining moment for proteomics, fulfilling the promise of measuring the proteome deeply, reproducibly, and at scale. This will allow unbiased proteomics to assume its central role at the core of the next generation of scientific and medical discovery, unleashing the full power of the proteome. The key capabilities of the new Proteograph Product Suite include higher throughput (doubling performance to over 1,000 samples/week/instrument), enhanced operational efficiency (60% lower per-sample cost), a fully automated workflow that significantly reduces operator-induced variability and ensures unmatched robustness for processing valuable biological samples, and a faster turnaround time (automated run time under 5 hours for 80-sample batches). Crucially, it provides deep, unbiased analysis, identifying up to 10 times more proteins than traditional mass spectrometry workflows. In conjunction with the product launch, Seer and its collaborators are set to unveil compelling new scientific data at ASMS 2025, showcasing the transformative impact of the Proteograph Product Suite in critical areas such as Alzheimer's disease, cancer research, and drug development.